Ceritinib - CAS 1032900-25-6
Catalog number: B0084-462148
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C28H36ClN5O3S
Molecular Weight:
558.14
COA:
Inquire
Targets:
ALK
Description:
This active molecular is a selective inhibitor of ALK(anaplastic lymphoma kinase)which is a target found in NSCLC (metastatic non-small cell lung cancer). The IC50 value is 200 pM in ALK enzymatic assays and 25 nM in cells. It less potently inhibits IGF-1R, InsR, and STK22D and IC50 value is 8, 7, and 23 nM. LDK378 is also minimally effective against a panel of other kinases. In Sep 2016, Interim adverse events and efficacy data from phase III ASCEND-4 trial in non small cell lung cancer released by Novartis. In Oct 2016, efficacy data from the phase III ASCEND-3 and ASCEND-5 trial in non small cell lung cancer was presented.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-462148 250 mg $298 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
A crystalline solid
Synonyms:
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine, LDK378,Zykadia,1380575-43-8 (2HCl), 1190399-48-4 (xHCl).
Solubility:
Soluble in DMSO
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Non small cell lung cancer
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
VERWOWGGCGHDQE-UHFFFAOYSA-N
InChI:
InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
Canonical SMILES:
CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
Current Developer:
Novartis; University of Texas Southwestern Medical Center
1.Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer.
Schaefer ES1, Baik C2. Cancer Manag Res. 2016 Mar 24;8:33-8. doi: 10.2147/CMAR.S96471. eCollection 2016.
Anaplastic lymphoma kinase (ALK) gene fusions occur in 3%-7% of non-small-cell lung cancer (NSCLC) cases. Ceritinib, a once-daily, oral ALK inhibitor, has activity against crizotinib-resistant and crizotinib-naïve NSCLC, including brain metastases. Ceritinib (Zykadia™) was granted accelerated approval by the US Food and Drug Administration in 2014 for treating crizotinib-resistant ALK-positive NSCLC. Adverse events (AEs), particularly gastrointestinal (GI) AEs, are commonly experienced at the recommended dose of 750 mg/d and ∼38% of patients require dose interruption or reduction for GI AEs. This case study details our experience with the use of proactive GI AE management regimens in patients treated with ceritinib (750 mg/d) across two study sites. Proactive Regimens A and B were implemented in patients with metastatic ALK-positive NSCLC treated with ceritinib to manage drug-related GI AEs. Regimen A comprised ondansetron and diphenoxylate/atropine or loperamide, taken 30 minutes prior to ceritinib dose.
2.Successful treatment with ceritinib after crizotinib induced hepatitis.
Sassier M1, Mennecier B2, Gschwend A2, Rein M3, Coquerel A4, Humbert X5, Alexandre J4, Fedrizzi S4, Gervais R6. Lung Cancer. 2016 May;95:15-6. doi: 10.1016/j.lungcan.2016.02.008. Epub 2016 Feb 23.
We report two cases of acute hepatitis induced by crizotinib in patients with ALK-rearranged non-small cell lung cancer (NSCLC) who were treated after by a second generation of ALK inhibitor without any incident. These cases suggest that ceritinib could be used as an alternative agent when crizotinib is responsible for hepatitis.
3.Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
Dong X1, Fernandez-Salas E2, Li E3, Wang S4. Neoplasia. 2016 Mar;18(3):162-71. doi: 10.1016/j.neo.2016.02.001.
Crizotinib is the first anaplastic lymphoma kinase (ALK) inhibitor to have been approved for the treatment of non-small cell lung cancer (NSCLC) harboring an ALK fusion gene, but it has been found that, in the clinic, patients develop resistance to it. Alectinib and ceritinib are second-generation ALK inhibitors which show remarkable clinical responses in both crizotinib-naive and crizotinib-resistant NSCLC patients harboring an ALK fusion gene. Despite their impressive activity, clinical resistance to alectinib and ceritinib has also emerged. In the current study, we elucidated the resistance mechanisms to these second-generation ALK inhibitors in the H3122 NSCLC cell line harboring the EML4-ALK variant 1 fusion in vitro. Prolonged treatment of the parental H3122 cells with alectinib and ceritinib led to two cell lines which are 10 times less sensitive to alectinib and ceritinib than the parental H3122 cell line. Although mutations of ALK in its kinase domain are a common resistance mechanism for crizotinib, we did not detect any ALK mutation in these resistant cell lines.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related ALK Products


CAS 1356962-20-3 AZD-3463

AZD-3463
(CAS: 1356962-20-3)

AZD-3463 is a potent ALK/IGF1R inhibitor with potential anticancer activity.

CAS 356559-13-2 SB-505124 hydrochloride

SB-505124 hydrochloride
(CAS: 356559-13-2)

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptor ALK5 and as well as being a selective inhibitor of ALK4 but with less pote...

CAS 1454846-35-5 Lorlatinib

Lorlatinib
(CAS: 1454846-35-5)

Lorlatinib is an ATP-competitive ROS1/ALK inhibitor with potential antitumor activity. Lorlatinib binds to both ALK and ROS1 kinases, resulting in disruption of...

CAS 1627503-67-6 LDN-214117

LDN-214117
(CAS: 1627503-67-6)

LDN-214117 is a selective and potent ALK2 inhibitor. LDN-214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM. There are currently no effective therapi...

CAS 1802220-02-5 TPX-0005

TPX-0005
(CAS: 1802220-02-5)

TPX-0005 is an orally available and potent ATP-competitive inhibitor of ALK/ROS1/TRK (IC50= 5.3 nM for SRC, IC50= 1.01 nM, 1.26 nM and 1.08 nM for mutant ALKs i...

CAS 1256580-46-7 Alectinib

Alectinib
(CAS: 1256580-46-7)

Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing ...

CAS 1097917-15-1 ASP-3026

ASP-3026
(CAS: 1097917-15-1)

ASP3026 is a novel and selective inhibitor for the ALK kinase. ASP3026 potently inhibited ALK kinase activity and was more selective than crizotinib in a Tyr-ki...

CAS 761439-42-3 TAE684

TAE684
(CAS: 761439-42-3)

NVP-TAE684 is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC(50) valu...

Belizatinib
(CAS: 1357920-84-3)

Belizatinib is inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Belizatinib can bind to and inhibit both ALK and TRK ki...

CAS 1256589-74-8 CH5424802 Hydrochloride

CH5424802 Hydrochloride
(CAS: 1256589-74-8)

CH5424802 Hcl (AF 802 Hcl; Alectinib Hcl) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.

CAS 1032900-25-6 Ceritinib

Ceritinib
(CAS: 1032900-25-6)

This active molecular is a selective inhibitor of ALK(anaplastic lymphoma kinase)which is a target found in NSCLC (metastatic non-small cell lung cancer). The I...

CAS 1356962-34-9 HG-14-10-04

HG-14-10-04
(CAS: 1356962-34-9)

HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM.

CAS 1062368-24-4 LDN193189

LDN193189
(CAS: 1062368-24-4)

LDN193189 is a selective and potent ALK inhibitor with potential anticancer activity.

R-268712
(CAS: 879487-87-3)

R-268712 is a potent and selective inhibitor of TGF-β type I receptor/ALK5 with an IC50 of 2.5 nM, an approximately 5000-fold more selectivity for ALK5 than p38...

CAS 1435934-00-1 LDN 193189 dihydrochloride

LDN 193189 dihydrochloride
(CAS: 1435934-00-1)

LDN 193189 dihydrochloride is a selective ALK2 and ALK3 inhibitor with IC50 values of 5 and 30 nM. It can inhibit FOP and ectopic ossification. LDN 193189 is a ...

CAS 1431985-92-0 K02288

K02288
(CAS: 1431985-92-0)

K02288 is a highly selective 2-aminopyridinebased inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concentrations similar to the current le...

CAS 1062368-49-3 ML347

ML347
(CAS: 1062368-49-3)

ML347 is a selective BMP receptor inhibitor with IC50 of 32 nM for ALK2, >300-fold selectivity over ALK3. Also inhibits ALK1 activity with IC50 of 46 nM.

CAS 1116235-97-2 GSK1838705A

GSK1838705A
(CAS: 1116235-97-2)

GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC50s of 2.0 and 1.6 nM, respectively. GSK1838705A blocks ...

CAS 856692-39-2 CEP-14083

CEP-14083
(CAS: 856692-39-2)

CEP-14083 is a ALK inhibitor. It has a potent activity against ALK in enzymatic assays (IC50 = 11 nmol/L). CEP-14083 can also inhibit the insulin receptor at a ...

BAY-754

BAY-754 is an ALK-1 inhibitor used as an anti-angiogenesis agent. It inhibited the eye vascular leakage in dose manner in mouse model.

Chemical Structure

CAS 1032900-25-6 Ceritinib

Quick Inquiry

Verification code

Featured Items